In a statement, CEO of Serine Therapeutics, Steve Ledger, said that the experimental treatment data indicates reliable improvement of patients’ daily function of patients
Serine Therapeutics announced on Tuesday, 26, that it had the support of US Food and Medicines Administration (FDA) to advance a clinical study program for the treatment of Parkinson’s disease.
In a statement, the biotechnology company said it plans to advance with the experimental treatment of the drug SER-252 (apomorphine) under the implementation of new FDA medicines.
“People living with advanced Parkinson need more consistent relief from motor fluctuations and our data so far suggest that SER-232 can more reliably improve daily function,” said Steve Ledger’s Serine Therapeutics CEO.
Unique opportunity
Legacy Card: Far beyond a service
Ledger said the development plan will be “rigorous and efficient in capital”, while generating “clinical and pharmacological” evidence to support the regulatory review.
